RESEARCH USE AND EDUCATIONAL DISCLAIMER
This article summarizes published scientific research for educational purposes only. Level Up Peptides products are intended exclusively for laboratory research by qualified researchers and are not for human or veterinary use. Discussion of published animal or human studies does not recommend those uses or establish the safety or effectiveness of any product sold on this website. This article does not provide medical advice, dosing guidance, or administration instructions.
SUMMARY
Thymosin alpha-1 has been investigated as an immune-modulating intervention in serious illness. Its research history includes suggestive early results and larger trials that did not demonstrate their primary clinical benefits. This review focuses on sepsis and severe acute pancreatitis studies, including the corrected 2025 TESTS report. The evidence should be read by disease, design and endpoint rather than reduced to a general promise of “immune boosting.” [1–4]
THE EARLIER SEPSIS SIGNAL
Wu and colleagues reported the ETASS trial in 2013. This multicenter, single-blind randomized study assigned 361 patients with severe sepsis to thymosin alpha-1 plus conventional care or the control regimen. The primary outcome was death from any cause within 28 days. [1]
Mortality was 26.0% in the thymosin alpha-1 group and 35.0% in the control group. The statistical interpretation was borderline: the nonstratified analysis gave a P value of 0.062, while the log-rank analysis gave 0.049. The reported relative-risk confidence interval included no effect. [1]
The investigators also observed improvement in a monocyte immune marker. This made further investigation reasonable, but the study did not justify treating the mortality effect as settled. Different analyses and the uncertainty around an estimate are part of the evidence, not details to remove from the summary.
THE LARGER PHASE 3 SEPSIS TRIAL
The 2025 TESTS publication by Wu and colleagues reported a double-blind, placebo-controlled trial across 22 centers in China. It enrolled 1,106 adults with sepsis; 1,089 who received study intervention were included in the modified intention-to-treat analysis. [2]
At 28 days, mortality was 23.4% with thymosin alpha-1 and 24.1% with placebo. The trial did not demonstrate a reduction in its primary mortality outcome. A May 2025 correction updated some data; the corrected hazard ratio was 0.97, with a 95% confidence interval from 0.76 to 1.24. The conclusion remained unchanged. [2,3]
This larger result deserves substantial weight when interpreting earlier encouraging reports. A proposed biological mechanism or a favorable small study cannot override a later controlled trial that directly tests the clinical question.
THE ACUTE PANCREATITIS TRIAL
Ke and colleagues reported a 2022 multicenter, double-blind randomized trial involving 508 patients with predicted severe acute necrotising pancreatitis. The study tested whether thymosin alpha-1 reduced infected pancreatic necrosis during the initial hospital admission. [4]
The primary complication occurred in 15.7% of participants receiving thymosin alpha-1 and 18.1% receiving placebo. The difference was not statistically significant. The study therefore did not establish the proposed preventive benefit in that population. [4]
This is a different disease and outcome from sepsis mortality. It should remain a separate result, while also illustrating why changes in immune biology do not automatically produce better clinical outcomes.
WHY IMMUNE MARKERS ARE NOT ENOUGH
Immune measurements can help investigators understand a response, identify a subgroup or develop a hypothesis. They are not substitutes for outcomes such as survival or avoidance of a serious complication when those are the claims being made.
A study may find a biological effect without showing a patient benefit. Conversely, a negative trial in one setting does not prove that every possible use is ineffective. The appropriate conclusion is specific: the tested intervention did not establish the particular benefit under those study conditions.
HOW TO READ THE CURRENT EVIDENCE
The selected trials do not support universal immune enhancement, infection prevention in healthy people or broad anti-aging claims. Further research would need a clearly defined population, meaningful endpoints and adequate safeguards against drawing conclusions from chance subgroup findings.
Thymosin alpha-1 should also remain distinct from Thymalin and the beta thymosins. Evidence belongs to the actual compound and formulation tested. Clinical research does not validate a separate laboratory product or establish its suitability for personal use. This article provides an educational account without treatment instructions.
REFERENCES
1. Wu J, Zhou L, Liu J, et al. The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial. Critical Care. 2013;17:R8.
https://doi.org/10.1186/cc11932
2. Wu J, Pei F, Zhou L, et al. The efficacy and safety of thymosin α1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial. BMJ. 2025;388:e082583.
https://doi.org/10.1136/bmj-2024-082583
3. BMJ. Correction: The efficacy and safety of thymosin α1 for sepsis (TESTS). 2025;389:r1098.
https://doi.org/10.1136/bmj.r1098
4. Ke L, Zhou J, Mao W, et al. Immune enhancement in patients with predicted severe acute necrotising pancreatitis: a multicentre double-blind randomised controlled trial. Intensive Care Medicine. 2022;48:899–909.
https://doi.org/10.1007/s00134-022-06745-7